Norman Moullan

Norman Moullan has a diverse work experience spanning over two decades. Norman currently serves as the Lead Translational Scientist at Aerium Therapeutics, a position they have held since April 2022. Prior to this, from June 2020 to April 2022, they worked at Nestlé Institute of Health Sciences S.A as a Translational Scientist/Metabolic Health Specialist in the Cardiometabolic Physiology group. In this role, they focused on the development of nutraceutical solutions for metabolic health and was involved in clinical study design, research strategy orientation, and scientific evaluation of external opportunities.

Before joining Nestlé, Norman worked at Labcorp Drug Development from February 2018 to May 2020 as a Clinical Study Coordinator EMEA - Global Project Management. In this position, they provided support in study feasibility assessment, study set-up, and monitoring of study milestones.

From February 2009 to February 2018, Norman Moullan was employed at the Ecole polytechnique fédérale de Lausanne as a Scientist & Lab project manager in the Laboratory of Integrative Systems Physiology. Norman'sresponsibilities included team management, hiring and supervision of laboratory staff, and preclinical drug development focused on metabolic diseases.

Prior to this, Norman held research assistant roles at the Center for Integrative Genomics (CIG) - University of Lausanne from 2005 to 2009 and at the Centre international de Recherche sur le Cancer / Organisation mondiale de la santé from 2000 to 2005.

Overall, Norman Moullan's work experience showcases their expertise in translational science, metabolic health, clinical study management, team leadership, and preclinical drug development.

Norman Moullan earned their Doctor of Philosophy (PhD) degree in Clinical and Industrial Drug Development from École Pratique des Hautes Études from 2011 to 2015. In addition, they obtained various certifications, including GCP-E6 (R2) in 2016 from Université de Neuchâtel-TRREE program, ICH-GCP E6 (R2) Training and Knowledge Check in 2019 from Covance, Informed Consent in 2019 from Université de Neuchâtel-TRREE program, Animal experimentation - LTK module 2 - FELASA accredited in 2015 from SCAV, Animal experimentation - LTK module 1 - FELASA accredited in 2008 from SCAV, and Good Clinical Practice in 2022 from NIDA Clinical Trials Network.